Sun Pharma announces US FDA Approval for Generic Mesalamine Extended Release Capsules

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies), announced that it has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Mesalamine Extended Release Capsules, 500 mg. The generic product approval is based on Pentasa® Extended Release Capsules, 500mg as a reference product.

As per March 2022 IQVIA Health data, Pentasa® Extended Release Capsules, 500mg had annualized sales of approximately US$ 213 million in USA.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 850.15 as compared to the previous close of Rs. 855.60. The total number of shares traded during the day was 65897 in over 4293 trades.

The stock hit an intraday high of Rs. 855.25 and intraday low of 835.25. The net turnover during the day was Rs. 55754311.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 FinalApproval USFDA ANDA MesalamineExtendedReleaseCapsules Pentasa